PHOENIX, November 14, 2013Avella Specialty Pharmacy today announced that it has been chosen by Pharmacyclics, Inc. and Janssen Biotech, Inc. as a select specialty pharmacy partner to dispense IMBRUVICA™ for its use in the treatment of patients with mantle cell lymphoma (MCL) who have received at least one prior therapy. IMBRUVICA is commercially available immediately and prescription referral forms can be found at www.avella.com/forms. Avella is one of five specialty pharmacy partners in the country to have access to the medication. 

“We are proud to be a specialty pharmacy provider of IMBRUVICA™ (ibrutinib) capsules, now approved by the U.S. Food and Drug Administration (FDA) for the treatment of patients with MCL,” stated Leslie Yendro, RN, VP, Business Development of Avella. “Avella has the ability to serve patients in all 50 states and to provide high-touch patient services and reliable product data to ensure maximum drug effectiveness. We are proud to launch IMBRUVICA™ with Pharmacyclics and their partner Janssen Biotech, Inc. and make this product available to oncology patients immediately.”

IMBRUVICA™ is a kinase inhibitor developed for the treatment of patients with MCL who have received at least one prior therapy. IMBRUVICA™ was one of the first medications to apply for FDA approval through the new Breakthrough Therapy Designation pathway. Please see the full prescribing information at www.IMBRUVICA.com.

As a specialty pharmacy provider of IMBRUVICA™, Avella will play a key role in patient care, ensuring optimum patient health. The specialty pharmacy will dispense the medication to patients as well as provide in-depth patient consultation. Eligible patients who are prescribed IMBRUVICA may receive access support through the YOU&I Access Program. More information is available at 1-877-877-3536 or at www.IMBRUVICA.com  

Specialty pharmacies play an important role in providing patients with complex medical conditions access to medications and in monitoring those patients to ensure correct utilization. Working as a key component of the healthcare system, Avella collaborates with providers, payors and patients to offer unique solutions to their challenges. More information about Avella and its specialty services can be found at www.avella.com.

About Avella Specialty Pharmacy
Headquartered in Phoenix, Arizona, Avella Specialty Pharmacy is a National Accredited Specialty Pharmacy, providing individualized care and support to patients since 1996. Avella's clinical pharmacists and staff members are experts in managing complex disease states and providing compassionate care. The company offers a nationwide distribution service to complement its retail locations. Avella reached 1,105th on Inc. magazine's 2013 list of the 5,000 fastest-growing private companies in the country. In addition, the Arizona Corporate Excellence Awards has named Avella Specialty Pharmacy as the fastest-growing private company based in the state. For more information, please visit www.avella.com.